title: Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease.
abstract: OBJECTIVE
  To examine ovarian reserve following chemotherapy in women with Hodgkin's disease.
  
  
  METHODS
  The study included nine patients who underwent ovarian tissue cryopreservation (OTCP) prior to chemotherapy consisting of the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) and co-treatment with gonadotropin-releasing hormone agonist (GnRH-a) (Group A), and 13 patients treated by the ABVD protocol only without GnRH-a (Group B). The average age was 25.2 +/- 2.7 years for the women in Group A and 31.8 +/- 6.8 years for those in Group B.
  
  
  RESULTS
  Six months following the end of chemotherapy, the menstrual cycle resumed in all Group A patients and in four Group B patients who had amenorrhea. Eight Group B patients had regular menses during and after chemotherapy. None of the patients suffered from ovarian failure. Two Group A patients conceived in the first year after completing chemotherapy.
  
  
  CONCLUSIONS
  Co-treatment with GnRH-a has little effect on ovarian protection in women with Hodgkin's disease.
authors.affiliation: Institute of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, 64239, Israel. azemf@tasmc.health.gov.il
authors.forename: Foad
authors.initials: F
authors.lastname: Azem
authors.forename: Nivin
authors.initials: N
authors.lastname: Samara
authors.forename: Tanya
authors.initials: T
authors.lastname: Cohen
authors.forename: Dalit
authors.initials: D
authors.lastname: Ben-Yosef
authors.forename: Beni
authors.initials: B
authors.lastname: Almog
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Lessing
authors.forename: Odeliya
authors.initials: O
authors.lastname: Goor
authors.forename: Ami
authors.initials: A
authors.lastname: Amit
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D015925:Cryopreservation; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000494:pharmacology; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010053:Ovary; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000517:prevention & control*; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001761:Bleomycin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone